168 related articles for article (PubMed ID: 2566380)
1. Differences between the promoting activities of the peroxisome proliferator WY-14,643 and phenobarbital in rat liver.
Cattley RC; Popp JA
Cancer Res; 1989 Jun; 49(12):3246-51. PubMed ID: 2566380
[TBL] [Abstract][Full Text] [Related]
2. Quantitative stereological analysis of the effects of age and sex on multistage hepatocarcinogenesis in the rat by use of four cytochemical markers.
Xu YH; Campbell HA; Sattler GL; Hendrich S; Maronpot R; Sato K; Pitot HC
Cancer Res; 1990 Feb; 50(3):472-9. PubMed ID: 1967547
[TBL] [Abstract][Full Text] [Related]
3. Increased susceptibility of aged rats to hepatocarcinogenesis by the peroxisome proliferator nafenopin and the possible involvement of altered liver foci occurring spontaneously.
Kraupp-Grasl B; Huber W; Taper H; Schulte-Hermann R
Cancer Res; 1991 Jan; 51(2):666-71. PubMed ID: 1985784
[TBL] [Abstract][Full Text] [Related]
4. Tumor promotion by the peroxisome proliferator nafenopin involving a specific subtype of altered foci in rat liver.
Kraupp-Grasl B; Huber W; Putz B; Gerbracht U; Schulte-Hermann R
Cancer Res; 1990 Jun; 50(12):3701-8. PubMed ID: 1971196
[TBL] [Abstract][Full Text] [Related]
5. Mitogenic and carcinogenic effects of a hypolipidemic peroxisome proliferator, [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio]acetic acid (Wy-14, 643), in rat and mouse liver.
Reddy JK; Rao MS; Azarnoff DL; Sell S
Cancer Res; 1979 Jan; 39(1):152-61. PubMed ID: 83907
[No Abstract] [Full Text] [Related]
6. [Dose-response relationship of promotion by phenobarbital in rat two-stage hepatocarcinogenesis].
Onodera H; Matsushima Y; Uneyama C; Shibutani M; Mitsumori K; Maekawa A; Hayashi Y
Eisei Shikenjo Hokoku; 1991; (109):55-60. PubMed ID: 1364405
[TBL] [Abstract][Full Text] [Related]
7. Comparative effects of L-methionine, S-adenosyl-L-methionine and 5'-methylthioadenosine on the growth of preneoplastic lesions and DNA methylation in rat liver during the early stages of hepatocarcinogenesis.
Pascale RM; Simile MM; Satta G; Seddaiu MA; Daino L; Pinna G; Vinci MA; Gaspa L; Feo F
Anticancer Res; 1991; 11(4):1617-24. PubMed ID: 1684097
[TBL] [Abstract][Full Text] [Related]
8. Hepatomegaly is an early biomarker for hepatocarcinogenesis induced by peroxisome proliferators.
Takagi A; Sai K; Umemura T; Hasegawa R; Kurokawa Y
J Environ Pathol Toxicol Oncol; 1992; 11(3):145-9. PubMed ID: 1625184
[TBL] [Abstract][Full Text] [Related]
9. Enhancement by Wy-14,643, a hepatic peroxisome proliferator, of diethylnitrosamine-initiated hepatic tumorigenesis in the rat.
Reddy JK; Rao MS
Br J Cancer; 1978 Oct; 38(4):537-43. PubMed ID: 728341
[TBL] [Abstract][Full Text] [Related]
10. Reversible alteration in the expression of the gap junctional protein connexin 32 during tumor promotion in rat liver and its role during cell proliferation.
Neveu MJ; Hully JR; Paul DL; Pitot HC
Cancer Commun; 1990; 2(1):21-31. PubMed ID: 1973356
[TBL] [Abstract][Full Text] [Related]
11. Age-related susceptibility to the carcinogenic effect of the peroxisome proliferator WY-14,643 in rat liver.
Cattley RC; Marsman DS; Popp JA
Carcinogenesis; 1991 Mar; 12(3):469-73. PubMed ID: 1849052
[TBL] [Abstract][Full Text] [Related]
12. Effects of alpha-tocopherol, phenobarbital, and butylated hydroxyanisole during promotion of diethylnitrosamine-initiated rat hepatocarcinogenesis.
Hendrich S; Duitsman P; Krueger SK; Jackson A; Myers RK
Nutr Cancer; 1991; 15(1):53-62. PubMed ID: 2017399
[TBL] [Abstract][Full Text] [Related]
13. Age-dependent induction of preneoplastic liver cell foci by 2-acetylaminofluorene, phenobarbital and acetaminophen in F344 rats initially treated with diethylnitrosamine.
Hasegawa R; Takahashi S; Imaida K; Yamaguchi S; Shirai T; Ito N
Jpn J Cancer Res; 1991 Mar; 82(3):293-7. PubMed ID: 1902451
[TBL] [Abstract][Full Text] [Related]
14. The natural history of neoplasia. Newer insights into an old problem.
Pitot HC
Am J Pathol; 1977 Nov; 89(2):402-11. PubMed ID: 21565
[TBL] [Abstract][Full Text] [Related]
15. Enhancement of rat hepatocellular-altered foci by the liver tumor promoter phenobarbital: evidence that foci are precursors of neoplasms and that the promoter acts on carcinogen-induced lesions.
Watanabe K; Williams GM
J Natl Cancer Inst; 1978 Nov; 61(5):1311-4. PubMed ID: 280716
[TBL] [Abstract][Full Text] [Related]
16. Hepatic effects of some [4-chloro-6-(2,3-xylidino)-2-pyrimidinylthio] acetic acid (WY-14,643) analogs in the mouse.
Reddy JK; Moody DE; Azarnoff DL; Tomarelli RM
Arch Int Pharmacodyn Ther; 1977 Jan; 225(1):51-7. PubMed ID: 851495
[TBL] [Abstract][Full Text] [Related]
17. The effect of the format of administration and the total dose of phenobarbital on altered hepatic foci following initiation in female rats with diethylnitrosamine.
Xu YD; Dragan YP; Young T; Pitot HC
Carcinogenesis; 1991 Jun; 12(6):1009-16. PubMed ID: 2044180
[TBL] [Abstract][Full Text] [Related]
18. Contrasting hepatocytic peroxisome proliferation, lipofuscin accumulation and cell turnover for the hepatocarcinogens Wy-14,643 and clofibric acid.
Marsman DS; Goldsworthy TL; Popp JA
Carcinogenesis; 1992 Jun; 13(6):1011-7. PubMed ID: 1600604
[TBL] [Abstract][Full Text] [Related]
19. Quantitative stereologic study of the effects of varying the time between initiation and promotion on four histochemical markers in rat liver during hepatocarcinogenesis.
Xu YH; Maronpot R; Pitot HC
Carcinogenesis; 1990 Feb; 11(2):267-72. PubMed ID: 1967985
[TBL] [Abstract][Full Text] [Related]
20. Hepatic peroxisome proliferation: induction by BR-931, a hypolipidemic analog of WY-14,643.
Reddy JK; Azarnoff DL; Sirtori CR
Arch Int Pharmacodyn Ther; 1978 Jul; 234(1):4-14. PubMed ID: 708142
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
